OBREDON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OBREDON (OBREDON).
Clonidine is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, leading to decreased peripheral vascular resistance and blood pressure.
| Metabolism | Clonidine is primarily metabolized by the liver via cytochrome P450 enzymes, with about 50% undergoing hepatic metabolism to inactive metabolites. |
| Excretion | Approximately 75% renal excretion as unchanged drug and metabolites, with 25% fecal elimination via biliary secretion. |
| Half-life | Terminal elimination half-life of 30 hours (range 24-36 hours), supporting once-daily dosing in chronic therapy. |
| Protein binding | 98% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5 L/kg (range 0.4-0.6 L/kg), indicating moderate distribution into total body water. |
| Bioavailability | Oral: 85% (range 80-90%) due to minimal first-pass metabolism; no intravenous formulation available. |
| Onset of Action | Oral: 1-2 hours to achieve peak plasma concentrations; clinical effect observed within 3-5 days of repeated dosing. |
| Duration of Action | Sustained for 24 hours after single oral dose, allowing once-daily administration; steady-state reached within 5-7 days. |
Adults: 10 mg orally once daily. For patients requiring more rapid relief, initial dose of 20 mg once daily may be used; switch to 10 mg once daily after 4 to 8 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment (CrCl <30 mL/min) due to lack of data. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate hepatic impairment (Child-Pugh B), use caution; maximum dose 5 mg once daily. Avoid use in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; however, consider potential for increased sensitivity and monitor renal function. Start at lower end of dosing range (10 mg once daily) if clinically appropriate. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OBREDON (OBREDON).
| Breastfeeding | Levonorgestrel is excreted into breast milk in small amounts (M/P ratio approximately 0.3). At typical doses, it is considered compatible with breastfeeding; however, based on the mechanism, it may reduce milk production. For emergency contraception, a single dose is unlikely to affect lactation significantly. Caution is advised during established lactation. |
| Teratogenic Risk | OBREDON (levonorgestrel) is a progestin-only contraceptive. No increased risk of major malformations has been observed in human studies. First trimester exposure is not associated with teratogenic effects; however, risk of ectopic pregnancy may be increased. Second and third trimester: no known fetal risks from the low systemic exposure resulting from use as an emergency contraceptive. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to clonidine","Severe bradycardia or sick sinus syndrome without a pacemaker"]
| Precautions | ["Rebound hypertension upon abrupt discontinuation","Sedation and drowsiness","Bradycardia and hypotension","Dry mouth","Constipation","Use caution in patients with cerebrovascular disease, renal impairment, or history of depression"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required for single-dose emergency contraception. For continuous use, monitor for pregnancy (including ectopic) and assess for abnormal uterine bleeding. No fetal monitoring indicated. |
| Fertility Effects | Levonorgestrel acts to prevent ovulation and may alter cervical mucus and endometrial receptivity. After a single dose for emergency contraception, there is an immediate, temporary disruption of the menstrual cycle that can affect fertility in the short term. With repeated use, ovulation suppression occurs. Fertility returns rapidly upon discontinuation. |